Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Epigenetic targets in hematopoietic malignancies

Oncogene volume 22, pages 6489–6496 (2003)Cite this article

Abstract

Frequent genetic alterations in hematopoietic neoplasias (chromosomal translocations, point mutations, etc.) have provided biologic targets for the development of effective novel therapies. A rapidly increasing body of knowledge provides evidence also for multiple epigenetic alterations in these disorders, which can complement or even precede genetic aberrations. Gene inactivation (‘silencing’) of tumor suppressor and growth inhibitory genes (e.g. the cyclin-dependent kinase inhibitors p16, p15, p21) is frequently mediated by DNA methylation of gene promoters. The acetylation state of histones (functionally linked to the DNA methylation state by the methylcytosine binding protein 2, recruiting histone deacetylases) provides a second major epigenetic silencing mechanism. Therapeutic reversal strategies are being developed for acute leukemias, myelodysplastic syndromes and malignant lymphomas. Since the discovery of the DNA methyltransferase (Dnmt) inhibitory activity of two azanucleosides (5-azacytidine, 5-aza-2′-deoxycytidine/decitabine) even at doses with minimal nonhematologic toxicity, both have been clinically studied in several myeloid neoplasias, particularly in elderly patients unable to tolerate aggressive treatment. Further development of agents counteracting aberrant methylation is directed at more targeted approaches, for example, antisense molecules against Dnmts. Histone deacetylases (HDACs) can be inhibited by numerous compounds (sodium phenylbutyrate, valproic acid, novel compounds such as depsipeptide), which have entered the clinical arena in similar indications as Dnmt inhibitors. Impressive effects of HDAC inhibition in acute promyelocytic leukemia models (PML/RARA expression) translate the finding of HDAC recruitment by this chimeric transcription factor to its target genes. The recent discovery of recruitment by PML/RARA also of Dnmt activity to the retinoic acid receptor-beta promoter makes it an interesting candidate for Dnmt inhibitors. Studies combining a ‘re-expressor’ strategy with inhibitors of Dnmts and HDACs are underway. Thus, resensitization to biological agents such as retinoids, colony-stimulating factors and other differentiation inducers may be envisioned.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Aoki E, Uchida T, Ohashi H, Nagai H, Murase T, Ichikawa A, Yamao K, Hotta T, Kinoshita T, Saito H and Murate T . (2000). Leukemia, 14, 586–593.

  • Au WY, Fung A, Man C, Ma SK, Wan TS, Liang R and Kwong YL . (2003). Br. J. Haematol., 120, 1062–1065.

  • Barlow DP . (1995). Science, 270, 1610–1613.

  • Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J and Yu AL . (1997). Cancer Res., 57, 832–836.

  • Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT and Chaubert P . (1999). Blood, 94, 1773–1781.

  • Baylin SB, Hoppener JW, de Bustros A, Steenbergh PH, Lips CJ and Nelkin BD . (1986). Cancer Res., 46, 2917–2922.

  • Baylin SB, Fearon ER, Vogelstein B, de Bustros A, Sharkis SJ, Burke PJ, Staal SP and Nelkin BD . (1987). Blood, 70, 412–417.

  • Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP . (1998). Adv. Cancer Res., 72, 141–196.

  • Bird AP . (1986). Nature, 321, 209–213.

  • Bird AP and Wolffe AP . (1999). Cell, 99, 451–454.

  • Camacho L, Ryan HJ, Chanel S, Maslak P, Salomoni P, Jakubowski A, Klimek V, Camastra D, Nimer S, Pandolfi PP and Pignet SL . (2001). Blood, 98, 460a abs 1924..

  • Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB . (1999). Nat. Genet., 21 (1), 103–107.

  • Chen H and Wu S . (2002). Chin. Med. J., 115, 987–990.

  • Chim CS, Liang R, Tam CY and Kwong YL . (2001). J. Clin. Oncol., 19, 2033–2040.

  • Chim CS, Liang R and Kwong YL . (2002). Hematol. Oncol., 20, 167–176.

  • Claus R, Fliegauf M, Stock M, Kolanczyk M and Lübbert M . (2003). Submitted.

  • Cross SH and Bird AP . (1995). Curr. Opin. Genet. Dev., 5, 309–314.

  • Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA and Lübbert M . (2002). Blood, 100, 2957–2964.

  • Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S and Pelicci PG . (2002). Science, 295, 1079–1082.

  • Drexler HG . (1998). Leukemia, 12, 845–859.

  • Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB and Herman JG . (2001). Cancer Res., 61, 4689–4692.

  • Esteller M . (2002). Oncogene, 21, 5427–5440.

  • Fan H, Guo X, Wu Q, Zhou T, Tan G, Wang L, Zhang X, Luo G and Xu M . (2000). Zhongguo Shi Yan Xue Ye Xue Za Zhi, 8, 271–274.

  • Garber K . (2002). J. Natl. Cancer. Inst., 94, 874–875.

  • Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J and Rivas C . (2002). Am. J. Pathol., 161, 1007–1013.

  • Gardiner-Garden M and Frommer M . (1987). J. Mol. Biol., 196, 261–282.

  • Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K and Miller CB . (2001). Clin. Cancer Res., 7, 2330–2339.

  • Goto T and Monk M . (1998). Microbiol. Mol. Biol. Rev., 62, 362–378.

  • Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T . (2001). EMBO J., 20, 6969–6978.

  • Graff JR, Herman JG, Myohanen S, Baylin SB and Vertino PM . (1997). J. Biol. Chem., 272, 22322–22329.

  • Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci PG . (1998). Nature, 391, 815–818.

  • Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD and Gazdar AF . (2002). Oncogene, 21, 4345–4349.

  • He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA, Marks PA, Richon VM and Pandolfi PP . (2001). J. Clin. Invest., 108, 1321–1330.

  • Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ and Baylin SB . (1997). Cancer Res., 57, 837–841.

  • Hoshino K, Asou N, Okubo T, Suzushima H, Kiyokawa T, Kawano F and Mitsuya H . (2002). Br. J. Haematol., 117, 531–540.

  • Issa JP, Baylin SB and Herman JG . (1997a). Leukemia, 11 (Suppl 1), S7–S11.

  • Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA and Baylin SB . (1997b). Cancer Res., 57, 1678–1681.

  • Issa JP . (1999). Crit. Rev. Oncol. Hematol., 32, 31–43.

  • Issa JP, Garcia-Manero G, Mannari R, Thomas D, Giles F, Cortes J, Estey E and Kantarjian H . (2001). Blood, 98, 594a.

  • Jaenisch R and Bird A . (2003). Nat. Genet., 33 (Suppl), 245–254.

  • Jahangeer S, Elliott RM and Henneberry RC . (1982). Biochem. Biophys. Res. Commun., 108, 1434–1440.

  • Jones PA, Wolkowicz MJ, Rideout III WM, Gonzales FA, Marziasz CM, Coetzee GA and Tapscott SJ . (1990). Proc. Natl. Acad. Sci. USA, 87, 6117–6121.

  • Jones PA and Laird PW . (1999). Nat. Genet., 21, 163–167.

  • Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J and Wolffe AP . (1998). Nat. Genet., 19, 187–191.

  • Jones PL and Wolffe AP . (1999). Semin. Cancer. Biol., 9, 339–347.

  • Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murthy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC and Marcucci G . (2003). Leukemia, 17, 350–358.

  • Kouzarides T . (2002). Curr. Opin. Genet. Dev., 12, 198–209.

  • Kündgen A, Strupp C, Aivado M, Habersang K, Junge B, Hildebrandt B, Haas R, Germing U and Gattermann N . (2003). Leuk. Res., 27 (Suppl. 1), S104.

  • Leone G, Teofili L, Voso MT and Lübbert M . (2002). Haematologica, 87, 1324–1341.

  • Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH and Evans RM . (1998). Nature, 391, 811–814.

  • Lübbert M, Brugger W, Mertelsmann R and Kanz L . (1996). Blood, 87, 447–455.

  • Lübbert M . (2000). Curr. Top. Microbiol. Immunol., 249, 135–164.

  • Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A . (2001). Br. J. Haematol., 114, 349–357.

  • Lübbert M, Wijermans WP, Engelhardt M and Otto F . (2002). Blood, 100 (Suppl. 1), 268b.

  • Malfoy B . (2000). J. Cell Sci., 113 (Part 22), 3887–3888.

  • Malumbres M, Perez de Castro I, Santos J, Melendez B, Mangues R, Serrano M, Pellicer A and Fernandez-Piqueras J . (1997). Oncogene, 14, 1361–1370.

  • Martinez-Delgado B, Robledo M, Arranz E, Osorio A, Garcia MJ, Echezarreta G, Rivas C and Benitez J . (1998). Leukemia, 12, 937–941.

  • Melki JR, Vincent PC and Clark SJ . (1999). Cancer Res., 59, 3730–3740.

  • Miller CB, Herman JG, Baylin SB, Galm O, Yerian JA and Gore SD . (2001). Blood, 98, 622a.

  • Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y and Sasaki H . (2001). Blood, 97, 1172–1179.

  • Najfeld V, Silverman LR, Scalise A and Lezon-Geyda K . (2002). Blood, 100 (Suppl.), 97a.

  • Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC and Huang DP . (1997). Blood, 89, 2500–2506.

  • Nguyen C, Liang G, Nguyen TT, Tsao-Wie D, Groshen S, Lübbert M, Zhou JH, Benedict WF and Jones PA . (2001). J. Natl. Cancer. Inst., 93, 1465–1472.

  • Nguyen TT, Mohrbacher AF, Tsai YC, Groffen J, Heisterkamp N, Nichols PW, Yu MC, Lübbert M and Jones PA . (2000). Blood, 95, 2990–2992.

  • Okano M, Bell DW, Haber DA and Li E . (1999). Cell, 99, 247–257.

  • Pfeifer GP, Steigerwald S, Boehm TLJ and Drahovsky D . (1988). Cancer Lett., 39, 185–192.

  • Pinto A, Maio M, Attadia V, Zappacosta S and Cimino R . (1984). Lancet, 2, 867–868.

  • Preisler HD, Li B, Chen H, Fisher L, Nayini J, Raza A, Creech S and Venugopal P . (2001). Leukemia, 15, 1589–1595.

  • Quesnel B, Guillerm G, Verecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M and Fenaux P . (1998). Blood, 91, 2985–2990.

  • Richel DJ, Colly LP, Kluin-Nelemans JC and Willemze R . (1991). Br. J. Cancer, 64, 144–148.

  • Robertson KD and Wolffe AP . (2000). Nat. Rev. Genet., 1, 11–19.

  • Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, Rodriguez Mdel C, Barrios M, Maldonado J and Torres A . (2002). Blood, 99, 2291–2296.

  • Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Fruhwald M, Costello JF, Held WA, Yu L, Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA and Plass C . (2001). Blood, 97, 3226–3233.

  • Sakashita K, Koike K, Kinoshita T, Shiohara M, Kamijo T, Taniguchi S and Kubota T . (2001). J. Clin. Invest., 108, 1195–1204.

  • Santini V, Kantarjian HM and Issa JP . (2001). Ann. Intern. Med., 134, 573–586.

  • Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K and Hasegawa Y . (2002). Oncogene, 21, 4822–4829.

  • Shaker S, Bernstein M, Momparler LF and Momparler RL . (2003). Leuk. Res., 27, 437–444.

  • Shen L, Kondo Y, Issa JP and Garcia-Manero G . (2002). Blood, 100 (9), 3432–3433.

  • Sigalotti L, Altomonte M, Colizzi F, Degan M, Zagonel V, Pinto A, Gattei V and Maio M . (2003). Blood. 104; 4644–4645.

  • Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA and Holland JF . (2002). J. Clin. Oncol., 20, 2429–2440.

  • Singal R and Ginder GD . (1999). Blood, 93, 4059–4070.

  • Sun B, Jiang G, Zaydan MA, La Russa VF, Safah H and Ehrlich M . (2001). Cancer Res., 61, 6931–6937.

  • Teofili L, Morosetti R, Martini M, Urbano R, Putzulu R, Rutella S, Pierelli L, Leone G and Larocca LM . (2000). Exp. Hematol., 28, 519–526.

  • Teofili L, Martini M, Di Mario A, Rutella S, Urbano R, Luongo M, Leone G and Larocca LM . (2001). Blood, 98, 495–497.

  • Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, Chen YC and Shen MC . (2001). Br. J. Haematol., 112, 148–154.

  • Toyota M, Ho C, Ohe-Toyota M, Baylin SB and Issa JP . (1999). Cancer Res., 59, 4535–4541.

  • Toyota M, Kopecky KJ, Toyata MO, Jair KW, Willman CL and Issa JP . (2001). Blood, 97, 2823–2829.

  • Uchida T, Knoshita T, Nagai H, Nakahara Y, Saito H, Hotta T and Murate T . (1997). Blood, 90, 1403–1409.

  • Wahlfors J, Hiltunen H, Heinonen E, Hämäläinen E, Alhoionen L and Jänne J . (1992). Blood, 80, 2074–2080.

  • Warrell RP Jr., He LZ, Richon V, Calleja E and Pandolfi PP . (1998). J. Natl. Cancer Inst., 90, 1621–1625.

  • Wijermans PW, Krulder JW, Huijgens PC and Neve P . (1997). Leukemia, 11, 1–5.

  • Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A . (2000). J. Clin. Oncol., 18, 956–962.

  • Wong IH, Ng MH, Huang DP and Lee JC . (2000). Blood, 95, 1942–1949.

Download references

Acknowledgements

We thank Bärbel Widmann for excellent help in manuscript preparation and Dr. Pierre Wijermans, The Hague, and Dr Peter A Jones, USC Los Angeles, for helpful discussions. M Lübbert is supported by Wilhelm-Sander-Stiftung, Deutsche Forschungsgemeinschaft and José Carreras Stiftung.

Author information

Authors and Affiliations

  1. Department Internal Medicine I, Division Hematology/Oncology, University of Freiburg Medical Center, Hugstetter Str., Freiburg, D-79106, Germany

    Rainer Claus & Michael Lübbert

Authors
  1. Rainer Claus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Lübbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Lübbert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Claus, R., Lübbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene 22, 6489–6496 (2003). https://doi.org/10.1038/sj.onc.1206814

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206814

Keywords

This article is cited by

Search

Advanced search

Quick links